Future studies must also aim to identify biomarkers predicting directional fidelity (ferroptosis→STING vs. STING→ferroptosis) across tissues, delineate mechanisms of crosstalk with other cell death or DNA repair pathways, and develop optimized combinatorial regimens (e.g., ferroptosis inducers + immunotherapy/STING modulators) that can maximize tumor-specific immune activation while avoiding pro-tumorigenic inflammation in translational models. Here, STING1 is linked to neoplasm.